Featured Research

from universities, journals, and other organizations

Possible new cancer treatment identified

Date:
April 19, 2012
Source:
Lund University
Summary:
New research findings show how it may be possible to render cancer tumors harmless without affecting the other cells and tissues in the body. The findings apply to cancers including breast, lung and bowel cancer. Many of the most common chemotherapy drugs used to treat cancer have serious side effects because they not only affect the cells in the cancer tumor, but also the cells in the rest of the body.

New research findings show how it may be possible to render cancer tumours harmless without affecting the other cells and tissues in the body. The findings apply to cancers including breast, lung and bowel cancer. The study was carried out at Lund University in Sweden.

Many of the most common chemotherapy drugs used to treat cancer have serious side effects because they not only affect the cells in the cancer tumour, but also the cells in the rest of the body.

Researchers at Lund University have now found a connection between two proteins that in different ways control cell division and the possibilities for a cancer tumour to develop. The retinoblastoma protein obstructs cell division and is absent in most types of cancer tumour. The new findings show that its absence leads to an increase in another protein, gamma-tubulin, which, when present in high levels, encourages the development of cancer tumours. However, if gamma-tubulin is blocked, the tumour cells die while the healthy cells survive.

The researchers are now looking for substances that can stop the effect of gamma-tubulin on cell division. This could form the basis for a new drug that works on various types of cancer and has a low risk of side effects if the substance is directed to the right place. This is because it is only the tumour cells that die.

"I judge the chances of finding a basis for a drug to be good, partly because there are already substances that block 'cousins' of gamma-tubulin," says Maria Alvarado-Kristensson, a researcher at Lund University, who believes that, if all goes well, a drug could be ready for initial tests on patients, known as 'phase 1 testing', in 5-6 years' time.

In the study, tissue and genetic material from patients with various different types of cancer were studied: breast cancer, bladder cancer, small-cell lung cancer, colon cancer and eye cancer. The two proteins were seen to play an important role in all these diseases and the protein is also found in a number of other types of cancer tumour.

"It is exciting to have research findings that are significant for several common types of cancer. This means that many patients will be affected if our work proves successful," says Maria Alvarado Kristensson.

The search for effective substances will involve screening a large number of substances, both natural and synthetic.


Story Source:

The above story is based on materials provided by Lund University. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. Ehlen, C. A. Rossello, K. von Stedingk, G. Hoog, E. Nilsson, H. M. Pettersson, K. Jirstrom, M. Alvarado-Kristensson. Tumors with non-functional RB1 are killed by reduced gamma-tubulin levels.. Journal of Biological Chemistry, 2012; DOI: 10.1074/jbc.M112.357038

Cite This Page:

Lund University. "Possible new cancer treatment identified." ScienceDaily. ScienceDaily, 19 April 2012. <www.sciencedaily.com/releases/2012/04/120419090715.htm>.
Lund University. (2012, April 19). Possible new cancer treatment identified. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/04/120419090715.htm
Lund University. "Possible new cancer treatment identified." ScienceDaily. www.sciencedaily.com/releases/2012/04/120419090715.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins